Navigation Links
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
Date:6/22/2009

Conference Call Today at 9:00am ET

Covers Europe, Middle East and Africa

Includes Licensing Option and Development Funding for NGX-1998

SAN MATEO, Calif. and STAINES, England, June 22 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma Inc. announced today that the companies have entered into an exclusive Distribution, Marketing and License agreement for the commercialization of Qutenza(TM) in the European Economic Area (EEA) including the 27 countries of the European Union, Iceland, Norway, and Liechtenstein as well as Switzerland, certain countries in Eastern Europe, the Middle East and Africa. The agreement closely follows the European Commission's approval received in May 2009, of Qutenza (capsaicin 179 mg) cutaneous patch for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal pain products.

Under terms of the agreement, Astellas will commercialize Qutenza in the above-mentioned territories and perform certain development of Qutenza including post-marketing commitments, to support Qutenza in the EU market. NeurogesX will receive EUR 30 million (approximately $42 million) for Qutenza commercialization rights, and EUR 5 million (approximately $7 million) for a license option of NGX-1998, the next-generation liquid formulation which uses the same active ingredient as Qutenza.

Astellas has an established and strong product portfolio with franchises in the therapeutic areas of urology, transplantation, dermatology and infectious disease. Commenting on the agreement, Masao Yoshida, President and CEO of Astellas Pharma Europe Ltd., said, "We are ver
'/>"/>

SOURCE NeurogesX, Inc.; Astellas Pharma Europe Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NeurogesX Reports Fourth Quarter and Year-End 2008 Results
2. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
3. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
5. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
6. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
7. Astellas Names Head of Global R&D Operations
8. Astellas Adds CNS Therapy Area Leader to Global R&D Team
9. Astellas Hires New Vice President of Compliance
10. Astellas Announces New Vice President of Marketing
11. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ire-FirstCall/ -- Centene Corporation (NYSE: C...ank of America Merrill Lynch 2009 Credit Conferenc...aza Hotel Times Square in New York City. ,, Cen...a.m. Eastern Time. Investors and other interested ...e,s presentation at: http://www.veracast.com/webc...
(Date:11/20/2009)...PRNewswire-USNewswire/ -- Samuel Gladding is no Sc...means to be "happy" during the holidays. As a lice...mily counseling and chair of the Department of Cou...esearch shows that it is the pressure to be happy ...ring the holidays. ,, That,s why he,s challengi...
(Date:11/20/2009)...wire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIR... Radio Reports: What Every Women Needs to Know A...teran journalist Perri Peltz. ,, (Logo: http:...O ) ,, Doctor Radio Reports: What Every Woma...ber 21 live at 10:00 am ET on Doctor Radio , SIRI...
(Date:11/20/2009)...yde used for embalming in the funeral industry wer...myeloid leukemia, according to a new study publish...nal Cancer Institute . , Previous studies have s...ignancies and brain cancer in anatomists, patholog...y have worked with formaldehyde. , For this st...
(Date:11/20/2009)...Emergency medical service (EMS) providers in the U...rrests each year. Only 5 to 10 percent of people ...ality cardiopulmonary resuscitation (CPR) provided...th better patient outcome. The Resuscitation Outc...arch network to study prehospital treatments for c...
Breaking Medicine News(10 mins):Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...ber 7 Misys (LSE: MSY), the,global application so...de,Processing product, for the second year in a ro...lution, Misys Confirmation Matching Service,(CMS) ...hnology,s readers were asked to vote on what they ...
... Opening a new, state-of-the-art cosm...d Reno, Nevada area, Dr. Tiffany McCormack hits th...n one of the nation’s leading publications. ...ive experience and credentials are generating buzz...
... Advances in prevention, detection an...ncer; Allsup honors cancer survivors by celebratin... Belleville, Ill. (PRWEB) November 7,...p , a national Social Security Disability Insuranc...
... Nov. 6 Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ...ng,supporter of a new entity, created by the Ameri...ing for post-graduate orthopaedic fellowships and,...eive and analyze funding requests before making gr...
...PICK: Visualizing asthma-causing immune cells at w...central role in causing asthma. Now, a team of res..., has developed approaches to noninvasively visual...they hope that these approaches might be developed...
...WICK, N.J., Nov. 6 Savient,Pharmaceuticals, Inc. ...Clement, President and Chief Executive Officer of ...pdate at the upcoming Credit Suisse Phoenix,Health...rizona,Biltmore Resort, November 11-14, 2008., In...
Other Medicine News:Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 3Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 4Health News:More People Living Longer After Cancer Diagnosis 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3Health News:JCI online early table of contents: Nov. 6, 2008 2Health News:JCI online early table of contents: Nov. 6, 2008 3Health News:JCI online early table of contents: Nov. 6, 2008 4Health News:JCI online early table of contents: Nov. 6, 2008 5Health News:Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th 2
(Date:11/20/2009)...Newswire-FirstCall/ -- BD (Becton, Dickinson and C...ion of its acquisition of HandyLab, Inc., an Ann A...ufactures molecular diagnostic assays and automati...nnounced an exclusive agreement for BD to develop ... Jaguar(TM) platform, the first fully integrated m...
(Date:11/20/2009)...swire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin ...known as DOR BioPharma, Inc., a late-stage biotech... a consortium to develop thermostable technology t...nes. Soligenix received a $9.4 million grant from ...iseases (NIAID), a division of the National Instit...
(Date:11/19/2009)...wswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc...a public offering of 5,000,000 shares of its commo...ceeds of $48.75 million. All of the shares are be...helf registration statement previously filed with ...has also granted the underwriters a 30-day option ...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3High Incidence of Obstructive Sleep Apnea in Suburban Dental Practices 50614 1High Incidence of Obstructive Sleep Apnea in Suburban Dental Practices 50614 2Unexpectedly long range effects in advanced magnetic devices 12876 1Orlowski of Albany to Become Head of Organ Donation Association 50613 1Orlowski of Albany to Become Head of Organ Donation Association 50613 2
...ide best science available, BETHESDA, Md., March ...y methodology for CNS clinical trials, United BioS... a European Advisory Board for,Data Quality. This ...ts,ongoing efforts to improve data quality and out...ements as pivotal endpoints, such as those in,psyc...
...Inc. (Nasdaq: ANSV ) today announced the initiati..., its long-acting, non-opioid analgesic,drug candi...The,multicenter, double-blind, placebo-controlled ...ea in reducing post-surgical pain in patients,unde...esigned to provide,pain relief for weeks to months...
Other Medicine Technology:UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy 2Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy 3Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy 4Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy 5
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: